Craig M Crews
Overview
Explore the profile of Craig M Crews including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
151
Citations
10738
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krone M, Crews C
Cell Chem Biol
. 2024 Nov;
32(2):219-226.
PMID: 39500325
Targeted protein degradation (TPD) has greatly advanced as a therapeutic strategy in the past two decades, and we are on the cusp of rationally designed protein degraders reaching clinical approval....
2.
Douglas T, Zhang J, Wu Z, Abdallah K, McReynolds M, Gilbert W, et al.
bioRxiv
. 2024 Oct;
PMID: 39416039
Metabolic stress must be effectively mitigated for the survival of cells and organisms. Ribosomes have emerged as signaling hubs that sense metabolic perturbations and coordinate responses that either restore homeostasis...
3.
Li K, Krone M, Butrin A, Bond M, Linhares B, Crews C
J Am Chem Soc
. 2024 Aug;
146(36):24884-24891.
PMID: 39190582
Type I melanoma antigen (MAGE) family members are detected in numerous tumor types, and expression is correlated with poor prognosis, high tumor grade, and increased metastasis. Type I MAGE proteins...
4.
Raina K, Forbes C, Stronk R, Rappi Jr J, Eastman K, Zaware N, et al.
Cell Chem Biol
. 2024 Aug;
31(8):1490-1502.e42.
PMID: 39116881
We describe a protein proximity inducing therapeutic modality called Regulated Induced Proximity Targeting Chimeras or RIPTACs: heterobifunctional small molecules that elicit a stable ternary complex between a target protein (TP)...
5.
Hu Z, Chen P, Li W, Krone M, Zheng S, Saarbach J, et al.
Sci Adv
. 2024 Mar;
10(13):eadj7251.
PMID: 38536914
We recently developed a heterobifunctional approach [phosphorylation targeting chimeras (PhosTACs)] to achieve the targeted protein dephosphorylation (TPDephos). Here, we envisioned combining the inhibitory effects of receptor tyrosine kinase inhibitors (RTKIs)...
6.
Chase D, Bebenek A, Nie P, Jaime-Figueroa S, Butrin A, Castro D, et al.
Angew Chem Int Ed Engl
. 2024 Feb;
63(14):e202316496.
PMID: 38348945
Brachyury is an oncogenic transcription factor whose overexpression drives chordoma growth. The downmodulation of brachyury in chordoma cells has demonstrated therapeutic potential, however, as a transcription factor it is classically...
7.
Chirnomas D, Hornberger K, Crews C
Nat Rev Clin Oncol
. 2023 Feb;
20(4):265-278.
PMID: 36781982
Heterobifunctional protein degraders, such as PROteolysis TArgeting Chimera (PROTAC) protein degraders, constitute a novel therapeutic modality that harnesses the cell's natural protein-degradation machinery - that is, the ubiquitin-proteasome system -...
8.
Hu Z, Chen P, Li W, Douglas T, Hines J, Liu Y, et al.
J Am Chem Soc
. 2023 Feb;
PMID: 36753634
Microtubule-associated protein tau is essential for microtubule assembly and stabilization. Hyperphosphorylation of the microtubule-associated protein tau plays an important pathological role in the development of Alzheimer's disease and other tauopathies....
9.
Raina K, Forbes C, Stronk R, Rappi Jr J, Eastman K, Gerritz S, et al.
bioRxiv
. 2023 Jan;
PMID: 36711980
While specific cell signaling pathway inhibitors have yielded great success in oncology, directly triggering cancer cell death is one of the great drug discovery challenges facing biomedical research in the...
10.
Venkatachalapathy M, Crews C
Cell Res
. 2023 Jan;
33(4):267-268.
PMID: 36646761
No abstract available.